Skip to main content

Oluwatoyosi Adefunke Onwuemene

Associate Professor of Medicine
Medicine, Hematology
Box 3422 Med Ctr, Durham, NC 27710
Dept of Medicine, Durham, NC 27710

Selected Grants


Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialCo Investigator · Awarded by University of Maryland, Baltimore · 2022 - 2027

A Clinical Trial Readiness Study of Patient Reported Outcome Measures in Thrombotic Thrombocytopenic Purpura (TTP)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2026

Increasing Diversity in Clinical Trials Participation through the SCD-CARRE Study

ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Foundation · 2023 - 2026

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialCo Investigator · Awarded by University of Pittsburgh · 2020 - 2022

American Society for Apheresis (ASFA) Heparin Induced Thrombocytopenia Registry

ResearchPrincipal Investigator · Awarded by American Society for Apheresis · 2019 - 2020

Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia

ResearchPrincipal Investigator · Awarded by Hemophilia & Thrombosis Research Society · 2017 - 2020

Core Clinical Centers for the CTSN

ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2018

Cellular Basis of HIT Immune Response in Cardiac Surgery

ResearchPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2012 - 2017

Population-based Surveillance And Outcomes of Venous Thromboembolism

ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2012 - 2015

External Relationships


  • Coag Coach LLC
  • Sanofi

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.